Page last updated: 2024-09-04

edotreotide and Cancer of Digestive System

edotreotide has been researched along with Cancer of Digestive System in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C	1

Trials

1 trial(s) available for edotreotide and Cancer of Digestive System

Article	Year
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:6 Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes	2014

Article

Year

Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:6

Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes

2014